Please ensure Javascript is enabled for purposes of website accessibility

Why Zynerba Pharmaceuticals Stock Is Crashing Today

By Keith Speights - Sep 18, 2019 at 11:50AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be worried about potential safety issues with its cannabinoid gel.

What happened

Shares of Zynerba Pharmaceuticals (ZYNE 3.39%) were crashing 18.3% lower as of 10:48 a.m. EDT on Wednesday after falling as much as 26.5% earlier in the morning. The big plunge came after Zynerba announced results from a phase 2 clinical study evaluating cannabinoid gel Zygel in treating children and adolescents with developmental and epileptic encephalopathy (DEE), a group of epilepsy syndromes linked with severe cognitive impairment and behavioral disturbances.

So what

CEO Armando Anido said that the company is "encouraged by the positive top-line results" of the Believe 1 phase 2 study of Zygel in DEE. How could the results be "positive" and Zynerba's shares fall so hard? It boils down to which part of the results receive the most attention.

Businessman looking at red line going through floor

Image source: Getty Images.

By the second month of treatment, patients in the Believe 1 study taking Zygel achieved a 44% median seizure reduction in focal impaired awareness and convulsive seizures. At least 42% of these patients experienced an improvement of 50% or more through the sixth month of treatment with Zygel.

Zynerba stated that Zygel "was well tolerated, and the safety profile was consistent with previously released data from Zygel clinical trials." But that statement doesn't sound as encouraging when you consider the detailed safety findings from the study.

Through six months of receiving treatment with Zygel, 96% of patients in the study experienced a treatment-emergent adverse event; 60% of patients experienced a treatment-related adverse event. Although Zynerba said that most of these adverse events were mild to moderate, 10 of the 46 patients reported serious adverse events. Many investors appeared to focus more heavily on the negative aspects of the safety profile for Zygel rather than the positive efficacy results.

Now what

It's quite possible that today's sell-off was overdone. Zynerba could bounce back some over the next few weeks. The company plans to complete its analysis of the data from the Believe 1 study and meet with the Food and Drug Administration sometime in the first half of 2020 to discuss a potential pathway to approval.

But investing in biotech stocks comes with plenty of risks. That's especially the case for biotechs like Zynerba that don't have a product on the market yet. Most investors will want to watch its progress with Zygel from the sidelines.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zynerba Pharmaceuticals, Inc. Stock Quote
Zynerba Pharmaceuticals, Inc.
$1.22 (3.39%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.